tbuckley/cabot-search huggingface dataset:
An open-label phase Ib/2 trial of TRC105 plus sorafenib in patients with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064).
Authors: Kanwal Pratap Singh Raghav, Richard T. Lee, Ravi Kumar Paluri, Kabir Mody, Brian Simpson, Bonne J. Adams, Charles P. Theuer, Ahmed Omar Kaseb
Journal: Journal of Clinical Oncology (2019)

268 Background: TRC105, an endoglin antibody, potentiates the activity of sorafenib (S) in preclinical HCC models, and TRC105 + S demonstrated a 33% partial response rate (5/15 pts) by RECIST, at RP2D doses of TRC105 in HCC pts ( Clin Can Res 2017). Adverse events characteristic of each drug were not increased in frequency or severity when the two drugs were administered concurrently. Methods: P1: Compare wkly TRC105 dosing vs four wkly doses followed by every other wkly dosing + S 800 mg daily. P2: Four objective responses are required in 21 pts to reject the null hypothesis that the true response rate probability is &lt; 5% with an alpha level of 0.1 and 80% power. Key inclusion criteria: disease not amendable to surgical or local therapies, ECOG ≤ 1; Child-Pugh A or B (7 points) classification. Results: Thirteen pts were enrolled in phase 1b at TRC105 10 mg/kg wkly for four doses and 15 mg/kg every other week thereafter + S. Mean serum levels of TRC105 exceeded the target conc. following 4 wkly doses of TRC105 at 10 mg/kg (mean = 34 µg/ml, range BLOQ-80). Mean trough conc. decreased following every other week dosing (mean = 13 µg/ml, range BLOQ-31), resulting in infusion reactions or a continued requirement for premedication. Therefore, wkly dosing of TRC105 at 10 mg/kg is the recommended Phase 2 dose. ADA were detected in 10 of 14 pts and correlated with lower than expected PK conc. Common TRC105 related AEs included ≤ G2 epistaxis, ≤ G2 fatigue and ≤ G2 headache. Common S related AEs included ≤ G3 fatigue, ≤ G3 hand foot syndrome and ≤G2 epistaxis. A total of 3 out of 14 evaluable patients (21%) enrolled in phase 1 and 2 achieved durable PR, 2 of these ongoing at week 45 and 17. Conclusions: TRC105 dosed at 10 mg/kg wkly was required to achieve target conc. due to higher clearance in HCC pts, which may have been influenced by a higher rate of ADA compared to studies of TRC105 in other tumor types. The combination of TRC105 + S demonstrated encouraging signs of activity, including durable PR in 2/9 evaluable pts in Phase 1b and 1/5 pts thus far in Phase 2. An additional 16 pts will be enrolled at the RP2D to assess the primary endpoint of ORR by RECIST. Clinical trial information: NCT01806064.
Penicillinase-producing gonococci in Britain, 1983.
Journal: BMJ (1984)

Disease Surveillance Centre and the Commuinicable Diseases (Scotland Unit Reports of penicillinase-producing strains of Neisseriagonorrhoeae in Britain doubled annually during the period 1977-82.' 2 The data for 1983 are summarised in the table.The total for the year was 1223, compared with 1033 in 1982, an increase of 18%,,.In men the increase was only 8%, but in women it was 32%,.
Comment: predictability of survival in the individual patient with lung cancer
Authors: P. Rubin
Journal: JAMA (1966)

The main hope for survival rests in the patient who has a resectable tumor without overt evidence of regional or distant metastases. Cliffton classifies this type of malignancy as stage I and notes that the lesion is "probably resectable with a good chance for cure." In analyzing the figures, only one of five in this category manage to survive five years. This is still a poor result. Are there any specific prognostic factors that determine longterm survival even in this highly selected group? The majority of reports indicate that there is no relationship between survival and age, sex, race, or duration of symptoms. Of pertinence is a recent report by Reinhoff et al (1965)<sup>14</sup>who studied the pathological specimens of resected lungs. Factors which appeared significant to long-term survival were<i>cell type</i>and<i>blood-vessel invasion</i>. Bronchiolar carcinoma carries a much better prognosis (87% survival) than adenocarcinoma and well differentiated
Abstract 1828: Genetic profiling of breast cancer confirms a pivotal role of EGFR pathway in the development of acquired resistance to tamoxifen
Authors: Abeer A. Bahnnasy, Ibrahim Malash, Nasr Al-Lahlouby, Osman Mansour, Sabry Shaarawy, Mona S. Abdellateif, Hend Yousef, Mai M. Lotfy, Rabab Gaafar, Mohamed. elsesy, Abdel-Rahman N. Zekri
Journal: Cancer Research (2019)

Abstract Background: Metastatic breast cancer (MBC) represents a major health problem in Egypt and worldwide. Prognostic and predictive factors for patients with MBC are highly needed, for better management and improved survival. The aim of this study was to assess the prognostic and predictive value(s) of CYP2D6 polymorphisms in MBC patients on Tamoxifen and to determine the genetic profile(s) of Tamoxifen responders and non-responders. Methods: We assessed 157 females with hormone receptor positive, locally recurrent inoperable and/or metastatic breast cancer (MBC) patients from Egypt for 1) CYP2D6 polymorphisms and 2) genetic aberrations in the EGFR pathway (92 genes). All patients received Tamoxifen and according to their response they were divided into Tamoxifen-responders and refractory. RNA was extracted from tumor and normal tissue samples and used to assess the genetic profiles of the patients using the SABioscience array (Qiagen) with four house-keeping genes. Results: 92(58.6%) patients were ER and PR positive, 51 (32.5%) were ER positive and 14 (8.9%) were PR positive. CYP2D6 *3/*4 was significantly prevalent in the refractory group (86.6%).Variants *10/*10 and *10/*3 were more common in the responders (85.5%) compared to refractory (P=0.027). CYP2D6 polymorphism associated significantly with Her-2 amplification (P&amp;lt;0.001), and reduced overall survival rate of patients in both refractory and responder groups (P&amp;lt; 0.001). Fifty-six genes were differentially over-expressed in the refractory group compared to responders, of which only JAK1, COL1A1, GAB1, FN1and MKNK1 showed a significant difference. In the refractory group 34 genes were differentially reduced compared to responders; none of them showed significant difference. Response to Tamoxifen associated significantly with disease site since patients with bone only disease showed better response than those with visceral metastases (P&amp;lt;0.005). Conclusion: A panel of 5 genes in EGFR pathway (MJAK1, COL1A1, GAB1, FN1 and MKNK1) together with CYP2D6 polymorphism scan predict response to Tamoxifen in metastatic BC patients though this has to be verified in an extended study including larger sample. Citation Format: Abeer A. Bahnnasy, Ibrahim Malash, Nasr Al-Lahlouby, Osman Mansour, Sabry Shaarawy, Mona S. Abdellateif, Hend Yousef, Mai M. Lotfy, Rabab Gaafar, Mohamed. elsesy, Abdel-Rahman N. Zekri. Genetic profiling of breast cancer confirms a pivotal role of EGFR pathway in the development of acquired resistance to tamoxifen [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1828.
News From JAMA’s Daily News Site
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical applicability of a methacholine inhalational challenge
Authors: J. R. Myers
Journal: JAMA (1981)

Cough, dyspnea, and chest pain are symptoms common to many cardiopulmonary diseases. A comprehensive evaluation, including a history, physical examination, ECG, chest roentgenogram, and pulmonary function studies, will often yield a specific diagnosis. However, when these symptoms are intermittent, as they often are in patients with bronchial asthma, the diagnosis may not be apparent. If asthma is thought to be a diagnostic possibility, a bronchial inhalation challenge should be used to demonstrate bronchial hyperreactivity, the hallmark of asthma. The methacholine chloride inhalation challenge is a simple and useful laboratory test to diagnose bronchial hyperreactivity. We describe eight patients with a variety of clinical symptoms to demonstrate the usefulness of this test. Patients with unexplained respiratory symptoms should be considered for bronchial inhalation challenge before proceeding to more invasive diagnostic procedures. (<i>JAMA</i>1981;246:225-229)
Book Review Four Treatises of Theophrastus von Hohenheim, Called "Paracelsus" . Translated from the original German, with introductory essays. By C. Lilian Temkin, George Rosen, Gregory Zilboorg, M.D. and Henry E. Sigerist, M.D. Edited, with a preface, by Henry E. Sigerist, M.D. 8°, cloth, 256 pp., with 1 portrait. Baltimore: The Johns Hopkins Press, 1941. $3.00.
Journal: New England Journal of Medicine (1943)
CHRONIC PARONYCHIA
Authors: A. J. E. BARLOW, F. W. CHATTAWAY, M. C. HOLGATE, T. ALDERSLEY
Journal: British Journal of Dermatology (1970)

Journal Article CHRONIC PARONYCHIA Get access A. J. E. BARLOW, A. J. E. BARLOW Department of Dermatology, Royal Infirmary, Huddersfield (Dr Barlow, Dr Holgate and Mr Aldersley), and Department of Biochemistry, University of Leeds (Dr Chattaway) Search for other works by this author on: Oxford Academic Google Scholar F. W. CHATTAWAY, F. W. CHATTAWAY Department of Dermatology, Royal Infirmary, Huddersfield (Dr Barlow, Dr Holgate and Mr Aldersley), and Department of Biochemistry, University of Leeds (Dr Chattaway) Search for other works by this author on: Oxford Academic Google Scholar M. C. HOLGATE, M. C. HOLGATE Department of Dermatology, Royal Infirmary, Huddersfield (Dr Barlow, Dr Holgate and Mr Aldersley), and Department of Biochemistry, University of Leeds (Dr Chattaway) Search for other works by this author on: Oxford Academic Google Scholar T. ALDERSLEY T. ALDERSLEY Department of Dermatology, Royal Infirmary, Huddersfield (Dr Barlow, Dr Holgate and Mr Aldersley), and Department of Biochemistry, University of Leeds (Dr Chattaway) Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 82, Issue 5, 1 May 1970, Pages 448–453, https://doi.org/10.1111/j.1365-2133.1970.tb02204.x Published: 01 May 1970 Article history Accepted: 10 November 1969 Published: 01 May 1970
CLINICAL MANIFESTATIONS OF FIBROMUSCULAR DYSPLASIA VARY BY PATIENT SEX: A REPORT OF THE UNITED STATES REGISTRY FOR FIBROMUSCULAR DYSPLASIA
Authors: Soo Hyun Kim, Jeffrey Olin, James Froehlich, Xiaokui Gu, J. Michael Bacharach, Bruce Gray, Michael Jaff, Barry Katzen, Eva Kline–Rogers, Pamela Mace, Alan Matsumoto, Robert McBane, Christopher White, Heather L. Gornik
Journal: Journal of the American College of Cardiology (2013)
Abstract P296: Dietary Habits in Primary Care Patients with Recent Intentional Weight Loss
Authors: Bethany Barone Gibbs, Dana Tudorascu, Cindy Bryce, Diane Comer, Gary Fischer, Rachel Hess, Kimberly A Huber, Kathleen M McTigue, Laurey R Simkin-Silverman, Molly B Conroy
Journal: Circulation (2017)

Introduction: Primary care physicians are uniquely positioned to provide counselling for weight loss, yet lifestyle habits of primary care patients with recent, intentional weight loss are unclear. Our objective was to characterize diet and exercise habits in primary care patients with recent, intentional weight loss, comparing those with greater (≥10%) to those with lesser (5 to &lt;10%) weight loss. Methods: This cross-sectional analysis of baseline data from a weight loss maintenance clinical trial in a primary care setting included patients,18-75 years old, with ≥5% intentional weight loss via lifestyle change in the past 2 years. Recent weight loss was confirmed with medical records. Dietary habits were measured by the Connor Diet Habits Survey. Results: Participants (n=192, 74% female, 87% white) had mean (SD) age 53 (12) years, body mass index 30.4 (5.9) kg/m 2 , and recent weight loss of 11 (8) %. Participants had a high burden of comorbidities: high blood pressure (50%), dyslipidemia (43%), diabetes (14%), and cardiovascular disease (10%). Participants reported high median intake of fruits and vegetables (5 servings/day), and low intake of fried foods (1 servings/wk), desserts (1 serving/wk) and sugar-sweetened beverages (0 serving/wk) (see Table) . Participants ate at restaurants on average twice/wk and most drank skim milk. Those with greater weight loss had higher intakes of fruits and vegetables (p=0.04) and low fat foods/recipes (p=0.02); other dietary habits were not related to amount of recent weight loss (see Table ). Conclusions: Despite the plethora of studies that support and refute a variety of dietary recommendations to promote weight loss, dietary habits in primary care patients with a high burden of comorbidities and recent, intentional weight loss were consistent with conventional wisdom including: more fruits and vegetables, limited added sugars, and more low fat foods and recipes. Future research should test the effects of this eating pattern in a primary care setting for weight loss and maintenance.
Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
Authors: Richard Aspinall, Mustafa Shennak, George Stocia, Dean Quinn, Lali Javashvili, Valentina Molteni, Chinweike Ukomadu, Bindi Sohal, Yiming Zhang, Miljen Martic, Alexandre Avrameas, Sheena Kao, Jacques Herve, Rachel Soon, Michael Badman
Journal: Journal of Hepatology (2020)
Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)
Authors: Paul J. Hesketh, Kari Chansky, Derick H. M. Lau, James H. Doroshow, Carol M. Moinpour, Robert A. Chapman, J Wendall Goodwin, Howard M. Gross, John J. Crowley, David R. Gandara
Journal: Journal of Thoracic Oncology (2006)
THE CRAIG COLONY FOR EPILEPTICS.
Authors: William P Spratling
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation
Authors: D. DeNetrio, F.-J. Morales, M. Komoun, J. Kearns, C. Dorozinsky, B.R. Rosengard, M.A. Acker, E. Loh
Journal: Journal of the American College of Cardiology (1998)
Cognitive dysfunction occurs early in experimentally induced NAFLD and is associated with systemic inflammation
Authors: Kristoffer Kjærgaard, Anne Catrine Daugaard Mikkelsen, Annie Landau, Peter Lykke Eriksen, Stephen Hamilton-Dutoit, Rajiv Jalan, Nils Erik Magnusson, Raj Mookerjee, Cecilie Bay-Richter, Karen Louise Thomsen
Journal: Journal of Hepatology (2020)
Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics
Authors: T. R. Beam
Journal: JAMA (1980)

Ten control volunteers and 40 insulin-dependent diabetics were immunized with polyvalent pneumococcal vaccine (Pneumovax). The populations were similar except that diabetics were significantly older. In a double-blind fashion, diabetics were divided into two groups of 20; one received vaccine at baseline and saline placebo four weeks later. The second received saline, then vaccine. Antibody response was measured by radioimmunoassay. In general, insulin-dependent diabetics responded as quickly and equally as controls. Antibody titers did not decline at eight weeks. Incidence and intensity of adverse reactions were similar among diabetics and controls. There was no correlation between antibody response and age (r=-.078), mean glucose concentration (r=-.096), or duration of diabetes (r=-.064). We conclude that insulin-dependent diabetics respond as well as controls to immunization with pneumococcal polysaccharide vaccine. (<i>JAMA</i>1980;244:2621-2624)
ADDRESS IN MEDICINE.
Authors: WILLIAM OSLER
Journal: JAMA (1897)

<h3>BRITISH MEDICINE IN GREATER BRITAIN.—THE MAKING OF GREATER BRITAIN.</h3> To trace successfully the evolution of any one of the learned professions would require the hand of a master, of one who, like Darwin, could combine the capacity for patient observation with philosophic vision. In the case of medicine the difficulties are enormously increased by the extraordinary development which belongs to the history of the present century. The rate of progress has been too rapid for us to appreciate, and we stand bewildered, and, as it were, in a state of intellectual giddiness, when we attempt to obtain a broad comprehensive view of the subject. In a safer "middle flight" it is my purpose to dwell on certain of the factors which have molded the profession in English-speaking lands beyond the narrow seas—of British Medicine in Greater Britain. Even for this lesser task (though my affiliations are wide and my sympathies
JOSEPH HYRTL (1810-1894) DESCRIPTIVE ANATOMIST
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medicine and the US Embargo Against Cuba
Authors: G. E. Martin
Journal: JAMA (1996)

<h3>To the Editor.</h3> —In his Commentary, Dr Chelala<sup>1</sup>offers a laudable if naive approach to improving Cuba's health situation, suggesting that providing food and medicine will help. That is like treating the complications of diabetes and not the hyperglycemia. The lack of food and medicine is not, popular wisdom notwithstanding, the result of the embargo, but of mismanagement by a centralized collective farming system and by the crushing economic burden of maintaining the most powerful armed forces in Latin America.<sup>2</sup>Cuba's widespread, rich, and varied soils, 200 inland rivers, and tropical rainfall allow for year-round cultivation of vegetables and other food crops,<sup>3</sup>yet only recently have farmers been allowed to grow some staples on small plots, not enough to meet the population's needs for vegetables and protein. Cuba should permit farmers to cultivate the land, without restrictions on what crops to grow or which livestock to raise,
Relationship Between Patient Mortality and Nurses' Level of Education—Reply
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ADDRESS ON DIETETICS.—MEDICAL FOOD ETHICS NOW AND TO COME.Delivered before the Section of Physiology and Dietetics of the American Medical Association, at its Forty-third Annual Meeting held at Detroit, Mich., June, 1892.
Authors: EPHRAIM CUTTER
Journal: JAMA (1893)

There is no doubt in my mind that most of the common diseases depend upon food for cause and cure save those from wounds, injuries, contagion and infection. Foods are substances, organic and inorganic, which, taken into the human body become normally changed into the normal tissues of that body and which sustain normal life. On this definition, air is food, water is food, common salt is food, all belonging to the mineral kingdom. It is clear that life cannot exist without air food, for example; cut off all air food from the sick and you cut off the sick from their life and disease. To put this more clearly take the Sections of this Association, in the order given by the Secretary inThe Journal: <i>Obstetrics and Diseases of Women</i>.—If I can judge from experience, difficult labors and gynecic diseases are largely due to bad feeding before and after